Mouse Model for ROS1-Rearranged Lung Cancer

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Arai, Yasuhito ^a   Totoki, Yasushi ^a   Takahashi, Hiroyuki ^a   Nakamura, Hiromi ^a   Hama, Natsuko ^a   Kohno, Takashi ^a   Tsuta, Koji ^b   Yoshida, Akihiko ^b   Asamura, Hisao ^b   Mutoh, Michihiro ^a   Hosoda, Fumie ^a   Tsuda, Hitoshi ^b   Shibata, Tatsuhiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; PROTEIN ROS1; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL STRAIN 3T3; CHROMOSOME 6Q; CHROMOSOME BAND; CONTROLLED STUDY; EMBRYO; EZR GENE; FUSION GENE; GENE REARRANGEMENT; GENETIC IDENTIFICATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERSTITIAL CHROMOSOME DELETION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; ROS1 GENE; SUBCUTANEOUS TISSUE TUMOR; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE MODELS, ANIMAL; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, TRANSGENIC; ONCOGENE FUSION; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84873927764     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056010     Document Type: Article

References (32)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global Cancer Statistics. CA Cancer J Clin 61: 69-90.
2. Janku F, Stewart DJ, Kurzrock R, (2010) Targeted therapy in non-small-cell lung cancer- is it becoming a reality? Nat Rev Clin Oncol 7: 401-414.
3. Gerber DE, Minna JD, (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18: 548-551.
4. Lovly CM, Carbone DP, (2011) Lung cancer in 2010: One size does not fit all. Nat Rev Clin Oncol 8: 68-70.
5. Sasaki T, Jänne PA, (2011) New strategies for treatment of ALK-rearranged non-small cell lung cancers. Clin Cancer Res 17: 7213-7218.
6. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small lung cancer. Nature 448: 561-566.
7. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, et al. (2007) Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12: 81-93.
8. Soda M, Takada S, Takeuchi K, Choi YL, Enomoto M, et al. (2008) A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci U S A 105: 19893-19897.
9. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131: 1190-1203.
10. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, et al. (2012) ROS1 Rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30: 863-870.
11. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, et al. (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med. 18: 378-381.
12. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, et al. (2012) Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Non-Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion. Clin Cancer Res 18: 4449-4457.
13. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, et al. (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22: 2109-2119.
14. Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, et al. (2012) Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer. Clin Cancer Res 18: 4570-4579.
15. Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, et al. (2012) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150: 1121-1134.
16. Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y,et al. (in press) ROS1-rearranged lung cancer: a clinicopathological and molecular study of 15 surgical cases. Am J Surg Path in press.
17. Maher CA, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, et al. (2009) Transcriptome sequencing to detect gene fusions in cancer. Nature 458: 97-101.
18. Chishti AH, Kim AC, Marfatia SM, Lutchman M, Hanspal M, et al. (1998) The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem Sci 23: 281-282.
19. Charest A, Kheifets V, Park J, Lane K, McMahon K, et al. (2003) Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci U S A. 100: 916-921.
20. Mishra A, Weaver TE, Beck DC, Rothenberg ME, (2001) Interleukin-5-mediated allergic airway inflammation inhibits the human surfactant protein C promoter in transgenic mice. J Biol Chem 276: 8453-8459.
21. Fehon RG, McClatchey AI, Bretscher A, (2010) Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 11: 276-287.
22. Medves S, Demoulin JB, (2012) Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med 16: 237-248.
23. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22: 508-515.
24. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, et al. (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16: 1561-1571.
25. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, et al. (2011) Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 35: 1226-1234.
26. Charest A, Lane K, McMahon K, Park J, Preisinger E, et al. (2003) Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 37: 58-71.
27. Gu TL, Deng X, Huang F, Tucker M, Crosby K, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6: e15640.
28. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, et al. (2011) Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One 6: e28250.
29. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, et al. (2009) Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor. Bioorg Med Chem Lett 19: 4720-4723.
30. Totoki Y, Tatsuno K, Yamamoto S, Arai Y, Hosoda F, et al. (2011) High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet 43: 464-469.
31. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, et al. (2005) A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65: 6071-6079.
32. Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, et al. (2009) Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signaling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer 100: 1257-1266.